Aclaris Therapeutics (ACRS) Getting Somewhat Positive Press Coverage, Accern Reports

News headlines about Aclaris Therapeutics (NASDAQ:ACRS) have trended somewhat positive on Friday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.6355184543518 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several analysts have recently weighed in on the company. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Monday. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Aclaris Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $39.20.

Shares of Aclaris Therapeutics (ACRS) opened at $25.51 on Friday. The firm has a market capitalization of $764.91 and a PE ratio of -11.81. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million for the quarter, compared to analyst estimates of $2.00 million. research analysts forecast that Aclaris Therapeutics will post -2.59 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply